MAOB and Parkinson disease: This prodrug has been shown to inhibit both AChE and BuChE, which, by decarbamylating this molecule, releases a phenol derivative of rasagiline, a monoamine oxidase B inhibitor (MAO-B), which is also used in Parkinson’s disease for its neuroprotective effect.